Contributions
Abstract: EP1578
Type: Poster Sessions
Abstract Category: Pathology and pathogenesis of MS - Biomarkers
Introduction: Multiple Sclerosis (MS) is the most common demyelinating disease in Denmark. MS is thought to be caused by a mixture of an overreactive proinflammatory immune response and a missing anti-inflammatory immune response which leads to infiltration of immune cells to the central nervous system (CNS) and a local destruction of myelin sheaths, oligodendrocytes and the blood-brain barrier (BBB). MicroRNAs (miRNAs) are short, non-coding RNA molecules that are involved in many biological processes including the immune system.
Objectives: So far, no specific MS biomarkers have been identified. Several studies have investigated the involvement of miRNAs in MS. In this study, we review studies that have measured miRNA levels in patients with clinically isolated syndrome (CIS) and MS patients with different disease courses and compare across disease groups as well as controls, furthermore miRNA levels in patients and controls following MS treatment and in different media such as whole blood, plasma, serum, blood leukocytes, white matter and cerebrospinal fluid.
Aims: The aim of this study is to investigate the use of miRNAs as biomarkers in MS diagnostics, predict treatment efficacy and determine disease prognosis of MS patients.
Methods: A structural litterature search was conducted in the bibliographic database PubMed using relevant keywords. Studies with subjects younger than 18 years of age, in vitro studies, solely animal studies, studies investigating other demyelinating diseases and certain foreign language studies were excluded.
Results: Many miRNAs were found to be dysregulated in MS patients. The most commonly dysregulated and investigated miRNAs included miR-155, miR-223, miR-146, let-7, miR-181, miR-30, miR-143, miR-15, miR-26 and miR-326. Several miRNAs were dysregulated when comparing MS patients with healthy subjects as well as when comparing with other disease controls or between different MS disease courses. Furthermore, several miRNAs in the investigated media. Additionally, a change in miRNA expression was observed following both first- and second-line treatments against MS as well as autologous hematopoietic stem cell transplantation (AHSCT).
Conclusions: Since MS is a multifactorial disease with different disease courses, unknown etiology and various results in the different studies, it is not possible to conclude whether miRNAs can be used as MS biomarkers. Further large controlled studies with well-established cohorts should be conducted.
Disclosure: Terese Kansing: Nothing to disclose in relation to this study.
Jette Lautrup Frederiksen: Nothing to disclose in relation to this study.
Abstract: EP1578
Type: Poster Sessions
Abstract Category: Pathology and pathogenesis of MS - Biomarkers
Introduction: Multiple Sclerosis (MS) is the most common demyelinating disease in Denmark. MS is thought to be caused by a mixture of an overreactive proinflammatory immune response and a missing anti-inflammatory immune response which leads to infiltration of immune cells to the central nervous system (CNS) and a local destruction of myelin sheaths, oligodendrocytes and the blood-brain barrier (BBB). MicroRNAs (miRNAs) are short, non-coding RNA molecules that are involved in many biological processes including the immune system.
Objectives: So far, no specific MS biomarkers have been identified. Several studies have investigated the involvement of miRNAs in MS. In this study, we review studies that have measured miRNA levels in patients with clinically isolated syndrome (CIS) and MS patients with different disease courses and compare across disease groups as well as controls, furthermore miRNA levels in patients and controls following MS treatment and in different media such as whole blood, plasma, serum, blood leukocytes, white matter and cerebrospinal fluid.
Aims: The aim of this study is to investigate the use of miRNAs as biomarkers in MS diagnostics, predict treatment efficacy and determine disease prognosis of MS patients.
Methods: A structural litterature search was conducted in the bibliographic database PubMed using relevant keywords. Studies with subjects younger than 18 years of age, in vitro studies, solely animal studies, studies investigating other demyelinating diseases and certain foreign language studies were excluded.
Results: Many miRNAs were found to be dysregulated in MS patients. The most commonly dysregulated and investigated miRNAs included miR-155, miR-223, miR-146, let-7, miR-181, miR-30, miR-143, miR-15, miR-26 and miR-326. Several miRNAs were dysregulated when comparing MS patients with healthy subjects as well as when comparing with other disease controls or between different MS disease courses. Furthermore, several miRNAs in the investigated media. Additionally, a change in miRNA expression was observed following both first- and second-line treatments against MS as well as autologous hematopoietic stem cell transplantation (AHSCT).
Conclusions: Since MS is a multifactorial disease with different disease courses, unknown etiology and various results in the different studies, it is not possible to conclude whether miRNAs can be used as MS biomarkers. Further large controlled studies with well-established cohorts should be conducted.
Disclosure: Terese Kansing: Nothing to disclose in relation to this study.
Jette Lautrup Frederiksen: Nothing to disclose in relation to this study.